BioMarin CLO sells 17,557 shares at $66.284

BIOMARIN PHARMACEUTICAL INC (BMRN) executive George Eric Davis, EVP and Chief Legal Officer, reported selling 17,557 shares of common stock on September 2, 2026 in an open market or private transaction at a weighted average price of $66.284 per share.

Rhea-AI Filing Summary

BIOMARIN PHARMACEUTICAL INC (BMRN) executive George Eric Davis, EVP and Chief Legal Officer, reported selling 17,557 shares of common stock on September 2, 2026 in an open market or private transaction at a weighted average price of $66.284 per share. After this sale, he directly holds 61,003 shares of BioMarin common stock. No Rule 10b5-1 trading plan is reported for this transaction. The footnote states the actual sale prices ranged from $66.271 to $66.39 per share.

Insider Trade Summary

Net Seller: 17,557 shares

Net Sell 1 txn

Insider Davis George Eric

Role EVP, Chief Legal Officer

Sold 17,557 shs ($1.16M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	17,557	$66.284	$1.16M

Holdings After Transaction: Common Stock — 61,003 shares (Direct)

Footnotes (1)

1. F1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

Key Figures

Shares sold: 17,557 shares Weighted average sale price: $66.284 per share Shareholding after transaction: 61,003 shares +1 more

4 metrics

Shares sold 17,557 shares Sale of BioMarin common stock on September 2, 2026

Weighted average sale price $66.284 per share Open market or private sale on September 2, 2026

Shareholding after transaction 61,003 shares Direct holdings of George Eric Davis following the sale

Sale price range $66.271–$66.39 per share Actual prices received within the reported weighted average

Key Terms

weighted average price, open market or private transaction, Rule 10b5-1

3 terms

weighted average price financial

"The price in column 4 is the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did BioMarin (BMRN) disclose for George Eric Davis?

BioMarin disclosed that George Eric Davis, EVP and Chief Legal Officer, sold 17,557 shares of common stock on September 2, 2026 in an open market or private transaction at a weighted average price of $66.284 per share.

How many BioMarin (BMRN) shares does George Eric Davis hold after this Form 4 transaction?

After the reported sale, George Eric Davis directly holds 61,003 shares of BioMarin common stock. This figure reflects his direct ownership position immediately following the September 2, 2026 transaction.

At what prices were the BioMarin (BMRN) shares sold in the September 2, 2026 transaction?

The filing reports a weighted average price of $66.284 per share. A footnote explains that the actual sale prices ranged from $66.271 to $66.39 per share, with full trade details available from the reporting person upon request.

Was the BioMarin (BMRN) insider sale by George Eric Davis under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction; the document-level Rule 10b5-1 checkbox is not marked as being made pursuant to such a plan.

What type of transaction did BioMarin (BMRN) report for George Eric Davis on the Form 4?

The Form 4 reports a sale of common stock, categorized as a non-derivative transaction and described as a sale in an open market or private transaction on September 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:43 PM Accepted by SEC EDGAR 09/03/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis George Eric

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CALIFORNIA 94901

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2026		S		17,557	D	$66.284(1)	61,003	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $66.271 to $66.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)